Results 251 to 260 of about 2,499,417 (342)

Plasma Proteomic Signatures for Alzheimer's Disease: Comparable Accuracy to ATN Biomarkers and Cross‐Platform Validation

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background There is growing recognition of the potential of plasma proteomics for Alzheimer's Disease (AD) risk assessment and disease characterization. However, differences between proteomics platforms introduce uncertainties regarding cross‐platform applicability.
Manyue Hu, Oliver Robinson, Christina M. Lill, Anna Matton, Raquel Puerta, Pilar Sanz, Merce Boada, Agustín Ruiz, Lefkos Middleton, for the Alzheimer's Disease Neuroimaging Initiative   +9 more
wiley   +1 more source

Correction: Pilot-scale cultivation of the snow alga <i>Chloromonas typhlos</i> in a photobioreactor. [PDF]

Front Bioeng Biotechnol
Schoeters F, Spit J, Azizah RN, Van Miert S.   +3 more
europepmc   +1 more source

Biotechnology: UN plans centre [PDF]

, 1981
Michael D. Stein
openalex   +1 more source

Correction to ‘In‐depth multiomic characterization of the effects of obesity in high‐fat diet‐fed mice’

FEBS Open Bio, EarlyView.
wiley   +1 more source

Development of a personalized visualization and analysis tool to improve clinical care in complex multisystem diseases with application to scleroderma

Arthritis Care &Research, Accepted Article.
Background In complex diseases, it is challenging to assess a patient's disease state, trajectory, treatment exposures, and risk of multiple outcomes simultaneously, efficiently and at the point of care. Methods We developed an interactive patient‐level data visualization and analysis tool (VAT) that automates illustration of a scleroderma patient's ...
Ji Soo Kim, John Scott, Lauren Fisher, Lauren N. Smith, Willie Stewart, Adrianne Woods, Rob Smithwright, Diane Koher, Parastoo Aslanbeik, Aalok B. Shah, Brad Tibbils, Samantha I. Pitts, Ayse P. Gurses, Yushi Yang, Ana‐Maria Orbai, Antony Rosen, Laura K. Hummers, Scott L. Zeger, Ami A. Shah   +18 more
wiley   +1 more source

Online Monitoring of Chip-Based Microscale Perfusion Fermentations. [PDF]

ACS Omega
Cramer SM, Gurav S, Glinsner D, Kochmann S, Mattanovich D, Hann S, Causon T.   +6 more
europepmc   +1 more source

ARC biotechnology: Cottage industry? [PDF]

, 1981
Robert Walgate
openalex   +1 more source

Prevalence, determinants and outcomes of low disease activity and remission attainment in SLE patients with clinically active disease

Arthritis Care &Research, Accepted Article.
Objectives This study aimed to identify the frequency and determinants of Lupus Low Disease Activity State (LLDAS) and Definition of Remission in SLE (DORIS‐remission) attainment in systemic lupus erythematosus (SLE) patients with clinically active disease, and the frequency and determinants of flare and damage accrual after target attainment.
Yanjie Hao, Dylan Hansen, Rangi Kandane‐Rathnayake, Worawit Louthrenoo, Yi‐Hsing Chen, Jiacai Cho, Aisha Lateef, Laniyati Hamijoyo, Shue Fen Luo, Yeong‐Jian Jan Wu, Sandra Navarra, Leonid Zamora, Zhanguo Li, Sargunan Sockalingam, Yasuhiro Katsumata, Masayoshi Harigai, Zhuoli Zhang, Madelynn Chan, Jun Kikuchi, Tsutomu Takeuchi, Sang‐Cheol Bae, Fiona Goldblatt, Sean O'Neill, Kristine (Pek Ling) Ng, Annie Law, BMDB Basnayake, Nicola Tugnet, Sunil Kumar, Cherica Tee, Michael Tee, Naoaki Ohkubo, Yoshiya Tanaka, Shirley Chan, CS Lau, Vera Golder, Alberta Hoi, Shereen Oon, Eric Morand, Mandana Nikpour, for the Asia Pacific Lupus Collaboration   +39 more
wiley   +1 more source

Corrigendum to "Maternal <i>Clostridium butyricum</i> supplementation during late gestation and lactation enhances gut bacterial communities, milk quality, and reduces piglet diarrhea" [Comput Struct Biotechnol J 27 (2025) 2933-2945]. [PDF]

Comput Struct Biotechnol J
Nuntapaitoon M, Chatthanathon P, Palasuk M, Wilantho A, Ruampatana J, Tongsima S, Settachaimongkon S, Somboonna N.   +7 more
europepmc   +1 more source

US biotechnology: Living with regulation [PDF]

, 1983
Peter David
openalex   +1 more source